Genetic profiles distinguish different types of hereditary ovarian cancer

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 885-895

  Domanska, Katarina ^a   Malander, Susanne ^a   Staaf, Johan ^a   Karlsson, Anna ^a   Borg, Åke ^a   Jönsson, Göran ^a   Nilbert, Mef ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

ArrayCGH; BRCA1; Hereditary non polyposis colorectal cancer; Heredity; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CHROMOSOME 17; CHROMOSOME 19; CLINICAL ARTICLE; CLUSTER ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC DISORDER; GENOMIC IN SITU HYBRIDIZATION; GENOMIC INSTABILITY; HUMAN; OVARY CANCER; PRIORITY JOURNAL;

ADULT; CARCINOMA; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA MISMATCH REPAIR; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 77957377822     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000934     Document Type: Article

References (47)

1. Bewtra C, Watson P, Conway T, Read-Hippee C and Lynch HT: Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 11: 180-187, 1992.
2. Lynch HT, Casey MJ, Snyder CL, et al: Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3: 97-137, 2009.
3. Whittemore AS: Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol 55: S15-S19, 1994.
4. Risch HA, McLaughlin JR, Cole DE, et al: Population brca1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98: 1694-1706, 2006.
5. Rubin SC, Benjamin I, Behbakht K, et al: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335: 1413-1416, 1996.
6. Pal T, Permuth-Wey J, Kumar A and Sellers TA: Systematic review and meta-analysis of ovarian cancers: estimation of micro- satellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res 14: 6847-6854, 2008.
7. Watson P, Butzow R, Lynch HT, et al: The clinical features of ovarian cancer in hereditary non-polyposis colorectal cancer. Gynecol Oncol 82: 223-228, 2001.
8. Moynahan ME, Cui TY and Jasin M: Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a BRCA1 mutation. Cancer Res 61: 4842-4850, 2001.
9. Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol 18 (Suppl. 2): S19-S32, 2005.
10. Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81: 214-218, 1999.
11. Moller P, Hagen AI, Apold J, et al: Genetic epidemiology of BRCA mutations, family history detects less than 50% of the mutation carriers. Eur J Cancer 43: 1713-1717, 2007.
12. Boyd J, Sonoda Y, Federici MG, et al: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283: 2260-2265, 2000.
13. Malander S, Ridderheim M, Masback A, et al: One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in southern Sweden. Eur J Cancer 40: 422-428, 2004.
14. Malander S, Rambech E, Kristoffersson U, et al: The contribution of the hereditary non-polyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 101: 238-243, 2006.
15. Jonsson G, Staaf J, Olsson E, et al: High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46: 543-558, 2007.
16. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A and Peterson C: Bioarray software environment (base): a platform for comprehensive management and analysis of microarray data. Genome Biol 3: Software0003, 2002.
17. Staaf J, Jonsson G, Ringner M and Vallon-Christersson J: Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics 8: 382, 2007.
18. Olshen AB, Venkatraman ES, Lucito R and Wigler M: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5: 557-572, 2004.
19. Saeed AI, Sharov V, White J, et al: TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378, 2003.
20. Diskin SJ, Eck T, Greshock J, et al: STAC: a method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res 16: 1149-1158, 2006.
21. Hauptmann S, Denkert C, Koch I, et al: Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 33: 632-641, 2002.
22. Mayr D, Hirschmann A, Lohrs U and Diebold J: KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 103: 883-887, 2006.
23. Schraml P, Schwerdtfeger G, Burkhalter F, et al: Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 163: 985-992, 2003.
24. Israeli O, Gotlieb WH, Friedman E, et al: Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH. Gynecol Oncol 90: 629-636, 2003.
25. Patael-Karasik Y, Daniely M, Gotlieb WH, et al: Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel. Cancer Genet Cytogenet 121: 26-32, 2000.
26. Van Beers EH, van Welsem T, Wessels LF, et al: Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 65: 822-827, 2005.
27. Wessels LF, van Welsem T, Hart AA, van't Veer LJ, Reinders MJ and Nederlof PM: Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 62: 7110-7117, 2002.
28. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J and Liu ET: Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 94: 990-1000, 2002.
29. Jonsson G, Naylor TL, Vallon-Christersson J, et al: Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 65: 7612-7621, 2005.
30. Abdel-Rahman WM, Ollikainen M, Kariola R, et al: Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene 24: 1542-1551, 2005.
31. Chan TL, Curtis LC, Leung SY, et al: Early-onset colorectal cancer with stable microsatellite DNA and near-diploid chromosomes. Oncogene 20: 4871-4876, 2001.
32. Schlegel J, Stumm G, Scherthan H, et al: Comparative genomic in situ hybridization of colon carcinomas with replication error. Cancer Res 55: 6002-6005, 1995.
33. Okuda T, Otsuka J, Sekizawa A, et al: P53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol 88: 318-325, 2003.
34. Brown LA, Kalloger SE, Miller MA, et al: Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 47: 481-489, 2008.
35. Ratnam K and Low JA: Current development of clinical inhibitors of poly(adp-ribose) polymerase in oncology. Clin Cancer Res 13: 1383-1388, 2007.
36. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M and De la Garza-Salazar J: Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 32: 180-190, 2006.
37. Dong Y, Walsh MD, McGuckin MA, et al: Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16ink4a in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 74: 57-63, 1997.
38. Niederacher D, Yan HY, An HX, Bender HG and Beckmann MW: CDKN2A gene inactivation in epithelial sporadic ovarian cancer. Br J Cancer 80: 1920-1926, 1999.
39. Quinn JE, James CR, Stewart GE, et al: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13: 7413-7420, 2007.
40. Massey A, Offman J, MacPherson P and Karran P: DNA mismatch repair and acquired cisplatin resistance in E. Coli and human ovarian carcinoma cells. DNA Repair (Amst) 2: 73-89, 2003.
41. Samimi G, Fink D, Varki NM, et al: Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 6: 1415-1421, 2000.
42. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20: 2310-2318, 2002.
43. Kurman RJ and Shih Ie M: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27: 151-160, 2008.
44. Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol 9: 1191-1197, 2008.
45. Levanon K, Crum C and Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: 5284-5293, 2008.
46. Dehari R, Kurman RJ, Logani S and Shih Ie M: The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 31: 1007-1012, 2007.
47. Scott M and McCluggage WG: Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data. Histol Histopathol 21: 81-92, 2006.